Clinical Trial Detail

NCT ID NCT02279433
Title A First-in-human Study to Evaluate the Safety, Tolerability and Pharmacokinetics of DS-6051b
Recruitment Active, not recruiting
Gender both
Phase Phase I
Variant Requirements yes
Sponsors Daiichi Sankyo Inc.
Indications

Advanced Solid Tumor

neuroendocrine tumor

colorectal cancer

non-small cell lung carcinoma

pulmonary large cell neuroendocrine carcinoma

Therapies

DS6051b

Age Groups: adult

Additional content available in CKB BOOST